Biomarker-Free Relacorilant Combo Broadens Options in Ovarian CancerByDr. Alexander B. OlawaiyeFebruary 5th 2026
ROSELLA Trial Extends Survival in Platinum-Resistant Ovarian CancerBySpencer FeldmanFebruary 5th 2026
NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBCByCURE staffFebruary 4th 2026